title: [Effectiveness of palifermin in the prevention of oral mucositis in patients with haematological cancers].
abstract: OBJECTIVE
  To assess the effectiveness of palifermin for the prevention of oral mucositis in patients with haematological cancers.
  
  
  METHODS
  Retrospective observational study of cohorts of patients with haematological cancer undergoing cytotoxic therapy causing hematopoietic ablation. The main variable assessed was the duration of the oral mucositis. Secondary variables assessed were incidence of mucositis, febrile or septic neutropenia and the administration of opioids and parenteral nutrition.
  
  
  RESULTS
  We included 36 patients in this study, 11 in the group that received palifermin and 25 in the control group. The duration of oral mucositis was 4.6+/-3.1 days (median: 5 days) in the patients treated with palifermin in comparison with 7.4+/-4.0 days (median: 6 days) in patients treated with conventional prophylactic therapy (p<0.05). However, no significant differences were seen in the incidence of mucositis, febrile or septic neutropenia, opioid administration of the use of parenteral nutrition.
  
  
  CONCLUSIONS
  Prophylactic treatment with palifermin reduces the duration of oral mucosities in patients with haematological cancer. Further studies are necessary with larger samples to be able to assess palifermin and its influence on other variables, such as incidence of mucositis, sepsis, febrile neutropenia, etc.
authors.affiliation: Servicio de Farmacia, Hospital General de Castellón, Castellón, España. daflo@postal.uv.es
authors.forename: D
authors.initials: D
authors.lastname: Ayago Flores
authors.forename: R
authors.initials: R
authors.lastname: Ferriols Lisart
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015331:Cohort Studies; D004198:Disease Susceptibility; D004341:Drug Evaluation; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009294:Narcotics / Q000627:therapeutic use; D009503:Neutropenia / Q000453:epidemiology; D010288:Parenteral Nutrition / Q000706:statistics & numerical data; D012189:Retrospective Studies; D018805:Sepsis / Q000453:epidemiology; D013280:Stomatitis / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy; D019172:Transplantation Conditioning / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D009294:Narcotics; D051523:Fibroblast Growth Factor 7